BioSpace News Archive

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will present posters for three of the company’s preclinical pipeline programs at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022.

CRISPR Therapeutics announced that it will present an e-poster at the American Association for Cancer Research 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.

Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that preclinical data from its Vaccibody™ vaccine platform technology will be presented at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced it will present a poster at the American Association of Cancer Research (AACR) Annual Meeting 2022 featuring new preclinical data on an allogeneic (off-the-shelf) TRuC-T cells, taking place on April 8-13, 2022 in New Orleans, Louisiana.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with clinical data of its innate cell engagers (ICE®) have been accepted for presentation at the annual meeting of the American Association for Cancer Research (AACR).

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present a poster and three oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the publication of the abstract highlighting the mechanism of action of MCLA-129 on the American Association for Cancer Research website.

Erasca, Inc. announced the company will present six poster presentations at the upcoming American Association for Cancer Research Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced that preclinical data demonstrating synergy between OKI-179, the Company’s oral Class I histone deacetylase (HDAC) inhibitor, and the MEK inhibitor, binimetinib, in NRAS melanoma models has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022.

Amgen (NASDAQ: AMGN) today announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans, Louisiana.